dr. (Annemieke) A van Dongen - Leunis
Assistant Professor Erasmus School of Health Policy & Management Health Technology Assessment (HTA)
- Location
- Burg. Oudlaan 50, Rotterdam
- Room
- J8-25
- Telephone
- +31104089763
- a.vandongen@eshpm.eur.nl
‹ Back to overview
Profile
Annemieke Leunis (1986) studied Health, Policy and Management at the Erasmus University in Rotterdam. She obtained her master’s degree in Health, Economics, Policy and Law in 2008 with the specialization Health Economics. After her graduation, Annemieke started working as a researcher at the institute for Medical Technology Assessment (iMTA). She is currently involved in cost-effectiveness analysis of new diagnostic technologies in an early phase of the development process. These new diagnostic technologies use genetic information to guide treatment decisions for patients with acute myeloid leukemia. In addition, she has performed some methodological research regarding the estimation of utilities for a cancer-specific questionnaire.…
Annemieke Leunis (1986) studied Health, Policy and Management at the Erasmus University in Rotterdam. She obtained her master’s degree in Health, Economics, Policy and Law in 2008 with the specialization Health Economics. After her graduation, Annemieke started working as a researcher at the institute for Medical Technology Assessment (iMTA). She is currently involved in cost-effectiveness analysis of new diagnostic technologies in an early phase of the development process. These new diagnostic technologies use genetic information to guide treatment decisions for patients with acute myeloid leukemia. In addition, she has performed some methodological research regarding the estimation of utilities for a cancer-specific questionnaire. Annemieke is also active in teaching and coordinating of the minor ‘The future of health: new medical technologies’ in the Bachelor programme.
- A. van Dongen - Leunis, W.K. Redekop & C.A. Uyl - de Groot (2016). Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30. Value in Health, 19 (6), 834-843. doi: 10.1016/j.jval.2016.05.008
- J.P. Postma, A. van Dongen - Leunis, L. Hakkaart - van Roijen & R.A. Bal (2016). Tussenrapportage TopZorg. (Extern rapport). Rotterdam: institute of Health Policy and Management
- A. Leunis. The cost-effectiveness of personalized medicine strategies in acute myeloid leukemia. EUR Prom./coprom.: prof.dr. C.A. de Uyl-de Groot, Prof. Dr. B. Lowenberg & dr. W.K. Redekop.
- N.C. Buyukkaramikli, J.G. Gaultney, A. Leunis & J.L. Severens (2014). Literature Review of Decision-Analytical Models Used in the Economic Evaluation of Empirical/Targeted Antifungal Treatments for Invasive Fungal Infections.
- A. Leunis, W.K. Redekop, C.A. de Uyl-de Groot & B. Lowenberg (2014). Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study. European Journal of Haematology, 93 (3), 196-206. doi: 10.1111/ejh.12324
- A. Leunis, W.K. Redekop, C.A.G.M. van Montfort, B. Lowenberg & C.A. de Uyl-de Groot (2013). The Development and Validation of a Decision-Analytic Model Representing the Full Disease Course of Acute Myeloid Leukemia. Pharmacoeconomics (Print). doi: 10.1007/s40273-013-0058-1
- A. Leunis, H.M. Blommestein, P.C. Huijgens, N.M.A. Blijlevens, M. Jongen-Lavrencic & C.A. de Uyl-de Groot (2013). The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands. Leukemia Research, 37, 245-250. doi: 10.1016/j.leukres.2012.09.018
- M.M. Versteegh, A. Leunis, J.J. Luime, M. Boggild, C.A. de Uyl-de Groot & E.A. Stolk (2012). Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making, 32, 554-568. doi: 10.1177/0272989X11427761
- M.M. Versteegh, A. Leunis, C.A. de Uyl-de Groot & E.A. Stolk (2012). Condition- Specific Preference-Based Measures: Benefit or Burden? Value in Health, 15, 504-513. doi: 10.1016/j.jval.2011.12.003
- A. Leunis & M. Varkevisser (2010). Internal Medicine Residents' Perceptions of the Learning Environment in Dutch Teaching Hospitals. Medical Teacher, 32, 90-94.
- A. van Dongen - Leunis, W.K. Redekop & C.A. Uyl - de Groot (2016). Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30. Value in Health, 19 (6), 834-843. doi: 10.1016/j.jval.2016.05.008
- J.P. Postma, A. van Dongen - Leunis, L. Hakkaart - van Roijen & R.A. Bal (2016). Tussenrapportage TopZorg. (Extern rapport). Rotterdam: institute of Health Policy and Management
- A. Leunis. The cost-effectiveness of personalized medicine strategies in acute myeloid leukemia. EUR Prom./coprom.: prof.dr. C.A. de Uyl-de Groot, Prof. Dr. B. Lowenberg & dr. W.K. Redekop.
- N.C. Buyukkaramikli, J.G. Gaultney, A. Leunis & J.L. Severens (2014). Literature Review of Decision-Analytical Models Used in the Economic Evaluation of Empirical/Targeted Antifungal Treatments for Invasive Fungal Infections.
- A. Leunis, W.K. Redekop, C.A. de Uyl-de Groot & B. Lowenberg (2014). Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study. European Journal of Haematology, 93 (3), 196-206. doi: 10.1111/ejh.12324
- A. Leunis, W.K. Redekop, C.A.G.M. van Montfort, B. Lowenberg & C.A. de Uyl-de Groot (2013). The Development and Validation of a Decision-Analytic Model Representing the Full Disease Course of Acute Myeloid Leukemia. Pharmacoeconomics (Print). doi: 10.1007/s40273-013-0058-1
- A. Leunis, H.M. Blommestein, P.C. Huijgens, N.M.A. Blijlevens, M. Jongen-Lavrencic & C.A. de Uyl-de Groot (2013). The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands. Leukemia Research, 37, 245-250. doi: 10.1016/j.leukres.2012.09.018
- M.M. Versteegh, A. Leunis, J.J. Luime, M. Boggild, C.A. de Uyl-de Groot & E.A. Stolk (2012). Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making, 32, 554-568. doi: 10.1177/0272989X11427761
- M.M. Versteegh, A. Leunis, C.A. de Uyl-de Groot & E.A. Stolk (2012). Condition- Specific Preference-Based Measures: Benefit or Burden? Value in Health, 15, 504-513. doi: 10.1016/j.jval.2011.12.003
- A. Leunis & M. Varkevisser (2010). Internal Medicine Residents' Perceptions of the Learning Environment in Dutch Teaching Hospitals. Medical Teacher, 32, 90-94.
- A. van Dongen - Leunis, W.K. Redekop & C.A. Uyl - de Groot (2016). Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30. Value in Health, 19 (6), 834-843. doi: 10.1016/j.jval.2016.05.008
- A. Leunis, W.K. Redekop, C.A. de Uyl-de Groot & B. Lowenberg (2014). Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study. European Journal of Haematology, 93 (3), 196-206. doi: 10.1111/ejh.12324
- A. Leunis, W.K. Redekop, C.A.G.M. van Montfort, B. Lowenberg & C.A. de Uyl-de Groot (2013). The Development and Validation of a Decision-Analytic Model Representing the Full Disease Course of Acute Myeloid Leukemia. Pharmacoeconomics (Print). doi: 10.1007/s40273-013-0058-1
- A. Leunis, H.M. Blommestein, P.C. Huijgens, N.M.A. Blijlevens, M. Jongen-Lavrencic & C.A. de Uyl-de Groot (2013). The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands. Leukemia Research, 37, 245-250. doi: 10.1016/j.leukres.2012.09.018
- M.M. Versteegh, A. Leunis, J.J. Luime, M. Boggild, C.A. Uyl - de Groot & E.A. Stolk (2012). Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making, 32 (4), 554-568. doi: 10.1177/0272989X11427761
- M.M. Versteegh, A. Leunis, J.J. Luime, M. Boggild, C.A. de Uyl-de Groot & E.A. Stolk (2012). Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making, 32, 554-568. doi: 10.1177/0272989X11427761
- M.M. Versteegh, A. Leunis, C.A. de Uyl-de Groot & E.A. Stolk (2012). Condition- Specific Preference-Based Measures: Benefit or Burden? Value in Health, 15, 504-513. doi: 10.1016/j.jval.2011.12.003
- A. Leunis & M. Varkevisser (2010). Internal Medicine Residents' Perceptions of the Learning Environment in Dutch Teaching Hospitals. Medical Teacher, 32, 90-94.
- J.P. Postma, A. van Dongen - Leunis, L. Hakkaart - van Roijen & R.A. Bal (2018). Eindrapportage experiment Topzorg. (Extern rapport). Rotterdam: Erasmus School of Health Policy and Management
- J.P. Postma, A. van Dongen - Leunis, L. Hakkaart - van Roijen & R.A. Bal (2016). Tussenrapportage TopZorg. (Extern rapport). Rotterdam: institute of Health Policy and Management
- A. Leunis. The cost-effectiveness of personalized medicine strategies in acute myeloid leukemia. EUR Prom./coprom.: prof.dr. C.A. de Uyl-de Groot, Prof. Dr. B. Lowenberg & dr. W.K. Redekop.
- N.C. Buyukkaramikli, J.G. Gaultney, A. Leunis & J.L. Severens (2014). Literature Review of Decision-Analytical Models Used in the Economic Evaluation of Empirical/Targeted Antifungal Treatments for Invasive Fungal Infections.
Praktijkstage Werken in de Zorg
- Title
- Praktijkstage Werken in de Zorg
- Year
- 2018
- Year level
- (bachelor 3)
Bachelorscriptie
- Title
- Bachelorscriptie
- Year
- 2018
- Year level
- (bachelor 3)
Health Technology Assessment
- Title
- Health Technology Assessment
- Year
- 2018
- Year level
- (master) (master) (master)
Advanced Health Economic Modelling
- Title
- Advanced Health Economic Modelling
- Year
- 2018
- Year level
- (master) (master) (master)
Health Technology Assessment (Eu-HEM)
- Title
- Health Technology Assessment (Eu-HEM)
- Year
- 2018
- Year level
- (master)
Advanced Health Economic Modelling EuHEM
- Title
- Advanced Health Economic Modelling EuHEM
- Year
- 2018
- Year level
- (master)
ESHPM Pre master
- Title
- ESHPM Pre master
- Year
- 2018
Assistant Professor
- University
- Erasmus University Rotterdam
- School
- Erasmus School of Health Policy & Management
- Department
- Health Technology Assessment (HTA)
- Country
- The Netherlands
- Telephone
- +31104089763